MET and non-small cell lung carcinoma: The efficacy and safety of capmatinib (INC280) in patients with NSCLC with the presence of a skipping mutation in exon 14 of the MET gene or a MET gene amplification was assessed in the open-label phase 2 clinical study GEOMETRY mono-1 [34].